Video IPO

Covering the Financial World

Clay Siegall Is A Natural Scientist With An Affinity To Help Cancer Patients Through Better Drug Development Researches

March 27, 2017 // by VideoIPOtv

Clay Siegall enjoys informative science articles a little bit more than he enjoys dining at sushi restaurants. His WordPress blog is indicative of his active search for new, exciting and revolutionary science finds in the world. Most recently, Dr. Clay Siegall enticed his readers with a more fun and interesting article about the discovery of the first fluorescent frog. Argentinian researchers have confirmed that the frog lights up in a bright blue light upon fluorescent lighting. The frog is a new case of study for scientists seeking to understand the chemistry of the animal. According to the report, the frog has hyloin-G1, hyloin-2, and hyloin-1 which helps it to re-emit shorter electromagnetic waves and longer wavelengths.

On a more serious note, Clay Siegall has a concern for the political well-being of his nation, like most Americans do. In an article he shared about Trump, the United States’ drop from the France Climate Change movement would influence participants worldwide. Other nations would lose interest in the ambition and only join under diplomatic pressure. However, the US has started its clean air initiative by the development of cleaner energies. Since 2005, US decreased its greenhouse emission by 21 percent.

According to a 2016 article BizJournals, Clay Siegall expanded his firm’s capability in cancer research by adding 100 more drugs. They developed Adcetris and anticipated it to have a massive impact in the medical market. Clay announced the development of two more drugs for the treatment of breast and bladder cancers. Clay’s Seattle is one of the fastest growing cancer research centers. Clay Siegall has grown Seattle Genetics to open branches in Europe.

Clay started Seattle as a vigorous scientific center in 1998. He heads as the CEO and chairman of the council. Under his leadership, Seattle has commercialized its ADCs in collaboration with Pfizer, GlaxoSmithKline, Abbvie, and Roche. Clay has a substantial investment in cancer research with his many contributions and fund raising events. He raised more than 1.2 billion dollars in a fundraising geared towards supporting research at Seattle Genetics. At the beginning of his quest, he contributed a million dollars to a lab in his hometown and promised to continue personifying philanthropy.

 

Leave a Reply